Related Experiment Videos

A cost analysis of coronary stenting without anticoagulation versus stenting with anticoagulation using warfarin

C M Goods1, M W Liu, S S Iyer

  • 1Division of Cardiovascular Diseases, University of Alabama of Birmingham 35294, USA.

Insights

Antiplatelet therapy after coronary artery stenting is more cost-effective than warfarin anticoagulation. Patients on antiplatelet therapy alone experienced shorter hospital stays and lower hospitalization costs.

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Economics

Background:

  • Coronary artery stenting necessitates antithrombotic therapy to prevent stent thrombosis.
  • Current guidelines offer various antithrombotic strategies, including antiplatelet therapy and anticoagulation.

Purpose of the Study:

  • To compare hospitalization costs and length of stay between antiplatelet therapy and warfarin anticoagulation post-coronary artery stenting.

Main Methods:

  • A case-controlled study design was employed.
  • Two groups of patients were compared: one managed with antiplatelet therapy only, and another treated with warfarin anticoagulation.
  • Hospitalization costs and length of hospital stay were the primary outcome measures.

Main Results:

  • Patients receiving antiplatelet therapy alone demonstrated significantly lower total hospitalization costs.
  • The average hospital stay was significantly reduced in the antiplatelet therapy group compared to the anticoagulation group.

Conclusions:

  • Antiplatelet therapy alone appears to be a more cost-effective strategy post-coronary artery stenting.
  • This approach is associated with reduced healthcare resource utilization, specifically shorter hospital stays and lower costs.

Related Concept Videos